DCAF13 and breast cancer: Overexpression of DCAF13 was associated with significantly worse prognosis in patients diagnosed with a subgroup of breast cancers (Chin et al., 2007; Wang et al., 2019) hepatocellular carcinoma (Cao et al., 2017; Qiao et al., 2019), and lung carcinoma (Li et al., 2020).